TRX-COBI

• Description :

  TRX-COBI ((R, R) -TRX-COBI; Trx-cobimetinib) is a MEK inhibitor targeting TRX fragments based on Fe2+. TRX-COBI has antitumor activity[1].

• Product Name Alternative :

  (R, R) -TRX-COBI; TRX-cobimetinib

• UNSPSC :

  12352005

• Target :

  MEK

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/trx-cobi.html

• Solubility :

  10 mM in DMSO

• Smiles :

  FC(C=C(C=C1)I)=C1NC(C(F)=C(C=C2)F)=C2C(N3CC([C@H]4N(C(O[C@H]5C[C@]6(OOC7([C@@H](C8)C[C@H]9C[C@@H]8C[C@@H]7C9)O6)CCC5)=O)CCCC4)(O)C3)=O

• Molecular Formula :

  C38H43F3IN3O7

• Molecular Weight :

  837.66

• References & Citations :

  [1]Jiang H, et al. Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors. J Exp Med. 2022 Apr 4;219 (4) :e20210739.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported